

# Janssen Pharmaceutical Companies of Johnson & Johnson

## Selected Novel Therapies - Recent Approvals/Potential Filings\*

### (2021-2025 Key Filings, As Outlined at 2021 Pharm Business Review)

Selective Highlights as of April 19, 2022

#### Novel Therapies APPROVED

##### Oncology

**RYBREVANT (amivantamab)**  
Non Small Cell Lung Cancer

US **CARVYKTI (Ciltacabtagene autoleucel)**  
Relapsed refractory Multiple Myeloma

#### Novel Therapies in REGISTRATION

##### Oncology

**CARVYKTI (Ciltacabtagene autoleucel)**  
EU Relapsed refractory Multiple Myeloma

**teclistamab (BCMA/CD3)**  
Relapsed refractory Multiple Myeloma

#### Novel Therapies PLANNED FILINGS

##### Cardiovascular and Metabolism

**RPGR AAV Gene Therapy**  
X-linked retinitis pigmentosa

**aprocitentan**  
Difficult to treat hypertension

**Milvexian (Factor XIa)**  
Prevention and Treatment of Thrombosis

##### Infectious Diseases and Vaccines

**RSV Adult Vaccine**  
RSV vaccine

**JNJ-3989 siRNA**

**HBV/HDV Co-infection**

##### Immunology

**nipocalimab**  
Warm Autoimmune Hemolytic Anemia

**Oral IL-23i**  
Psoriasis

##### Neuroscience

**seltorexant**  
Adjunctive treatment for major depressive disorder with insomnia symptoms

**Aticaprant**  
Adjunctive treatment for major depressive disorder

##### Oncology

**TAR-200 (RIS/gemcitabine)**  
Bladder Cancer

**talquetamab (GPRC5D/CD3)**  
Multiple myeloma

**niraparib**  
Metastatic castration-resistant prostate cancer (mCRPC)

##### Pulmonary Hypertension

**Macitentan 75mg**  
Pulmonary Arterial Hypertension



Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S; and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab); Lazertinib licensed from Yuhuan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx;